PDCD1 and cancer: A series of clinical studies have shown that anti-PD-1/PD-L1 antibodies demonstrate robust and long-lasting anti-cancer activities across several solid and hematological cancers, such as lung cancer (13), renal cell cancer (14), melanoma (15), hepatocellular carcinoma (16), and lymphoma (17).